Orthopaedic Institute of North Mississippi merging, rebranding
Following the merger, MSMOC will have 32 doctors and 33 advanced practice providers at 18 locations, creating the largest network of orthopedic specialists in the state and one of the most comprehensive in the Southeast.
Founded in 1984, Mississippi Sports Medicine has locations in Jackson, Flowood, Madison, Brookhaven, Ruleville and Yazoo City. MSMOC surgeons were the first of five in the U.S. and the first in Mississippi performing outpatient joint replacements. The group performs over half the total joint replacements in the state. It has the largest orthopaedic joint center in the country, the first in the state, and it was one of the first three centers in the U.S. to perform orthopaedic joint replacements.
Dr. Eric Lewis, fellowship-trained orthopedic hand surgeon at OINMS, said joining forces with MSMOC would benefit more people in the region.
'For decades, we have earned our reputation by providing exceptional, patient-focused care in Tupelo and across North Mississippi,' he said. 'Teaming up with Mississippi Sports Medicine will strengthen our statewide collaboration and expand access to cutting-edge treatments and specialized expertise for the region and people we serve.'
In a press release, OINMS said its physicians and staff "remain committed to the advanced orthopedic and sports medicine care their neighbors across the region have trusted for nearly three decades."
OINMS said Mississippi Sports Medicine had "built a reputation for orthopedic excellence through its clinics and fellowship programs, which have trained several orthopedic physicians in the area, and Oxford Ortho's team has been its region's leader since the 1990s. By partnering with their colleagues in Jackson and Oxford, the Tupelo team is able to extend its legacy across Mississippi and the Southeast."
As the three groups merge their operations over the next couple of months, patients will continue to be seen at the same locations by the same physicians.
"The name will change, but the same doctors that have been trusted by the Tupelo and North Mississippi community for decades will remain the same," the press release said.
'As someone who completed my sports medicine fellowship at Mississippi Sports Medicine, I'm excited to deepen our collaboration with the Jackson team,' said Dr. Bryan Fagan, an OINMS orthopedic surgeon. 'Together, we'll bring more innovation and specialized expertise to patients across North Mississippi.'
Leading up to the launch of the new brand on Aug. 4, residents and patients will see the new name on signage, materials and communications.
'Orthopedics is a team sport,' said Dr. J.R. Woodall, a spine surgeon based in Jackson. 'I've long respected the Oxford and Tupelo teams, and this evolution will unlock new opportunities in research, education and cutting-edge care for every Mississippian.'
Orthopaedic Institute of North Mississippi was born of a merger in 2018 when North East Orthopaedics and Sports Medicine and North Mississippi Sports Medicine and Orthopaedic Clinic of Tupelo joined forces and moved the practice to Midtown Pointe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
39 minutes ago
- CNBC
AI voice startup ElevenLabs pushes global expansion as it gears up for an IPO
LONDON — ElevenLabs, a London-based startup that specializes in generating synthetic voices through artificial intelligence, has revealed plans to be IPO-ready within five years. The company told CNBC it is targeting major global expansion as it prepares for an initial public offering. "We expect to build more hubs in Europe, Asia and South America, and just keep scaling," Mati Staniszewski, ElevenLabs' CEO and co-founder, told CNBC in an interview at the firm's London office. He identified Paris, Singapore, Brazil and Mexico as potential new locations. London is currently ElevenLabs' biggest office, followed by New York, Warsaw, San Francisco, Japan, India and Bangalore. Staniszewski said the eventual aim is to get the company ready for an IPO in the next five years. "From a commercial standpoint, we would like to be ready for an IPO in that time," he said. "If the market is right, we would like to create a public company … that's going to be here for the next generation." Founded in 2022 by Staniszewski and Piotr Dąbkowski, ElevenLabs is an AI voice generation startup that competes with the likes of Speechmatics and Hume AI. The company divides its business into three main camps: consumer-facing voice assistants, integrations with corporates such as Cisco, and tailor-made applications for specific industries like health care. Staniszewski said the firm hasn't yet decided where it could list, but that this decision will largely rest on where most of its users are located at the time. "If the U.K. is able to start accelerating," ElevenLabs will consider London as a listing destination, Staniszewski said. The city has faced criticisms from entrepreneurs and venture capitalists that its stock market is unfavorable toward high-growth tech firms. For example, Deliveroo, whose shares tanked nearly 30% when the company went public, was recently acquired by U.S. food delivery rival DoorDash for close to $4 billion. Meanwhile, British money transfer firm Wise last month said it plans to move its primary listing location to the U.S., ElevenLabs was valued at $3.3 billion following a recent $180 million funding round. The company is backed by the likes of Andreessen Horowitz, Sequoia Capital and ICONIQ Growth, as well as corporate names like Salesforce and Deutsche Telekom. Staniszewski said his startup was open to raising more money from VCs, but it would depend on whether it sees a valid business need, like scaling further in other markets. "The way we try to raise is very much like, if there's a bet we want to take, to accelerate that bet [we will] take the money," he said.
Business Wire
an hour ago
- Business Wire
Assetze Introduces ‘EOI', A New IT Model for Global Companies Entering India
BANGALORE, India--(BUSINESS WIRE)--Assetze, an India-based IT asset management company, has supported countless businesses in scaling and running smooth IT operations. Its intuitive SaaS platform enables centralized control and real-time visibility, with companies reporting up to 2x improvement in operational efficiency. Now, Assetze is introducing its latest offering: Employer of IT (EOI). A comprehensive backend model built specifically for companies expanding into India. EOI enables organizations to establish and scale their presence in India while entrusting their entire IT function to Assetze, from infrastructure setup to long-term support and maintenance. Expertise: Whether supporting a fast-growing global startup or an established enterprise, Assetze brings in-depth operational experience to deliver a reliable and compliant IT framework – with experience of serving over 150 companies across the globe. With an on-ground team managing setup, maintenance, and coordination, companies gain a dependable partner for all backend IT operations. Access: Beyond IT management, Assetze also offers Employer of Record (EOR) services, allowing companies to easily establish teams in India. The combination of EOI and EOR gives businesses a complete backend foundation for confidently launching and scaling operations. Results: EOI ensures that IT operations are aligned with security protocols and compliance standards from day one. By eliminating the need for multiple vendors or in-house IT teams, the model simplifies scaling while reducing operational risk and complexity. Several Y Combinator-backed companies already rely on Assetze for IT support, procurement, AI Infra, E-waste, and maintenance services across India. Jagadish V, one of the company's co-founders, expressed, 'Our EOI model has made it effortless for our global clients to establish reliable IT operations in India without building from scratch. It's a new and unique approach to solving a very real problem faced by companies looking to take advantage of India's skilled workforce.'
Business Upturn
2 hours ago
- Business Upturn
Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence
Alembic Pharmaceuticals Inc., the wholly owned US subsidiary of Alembic Pharmaceuticals Limited, has announced the acquisition of UK-based Utility Therapeutics Ltd. This strategic move marks Alembic's entry into the branded anti-infective segment in the United States, particularly focusing on treatments for urinary tract infections (UTIs). Utility Therapeutics is engaged in developing pharmaceutical products aimed at combating UTIs, a widespread medical condition in the US. The acquisition brings two key assets into Alembic's fold — 'Pivya,' an FDA-approved treatment for uncomplicated UTIs, and 'MEC,' a pipeline product currently under development to address complicated UTI cases. Alembic Pharmaceuticals sees this acquisition as a significant step towards strengthening its presence in the US market with branded specialty products. The deal allows Alembic to market Utility's assets in the US, leveraging the regulatory approvals already in place and continuing the development of promising pipeline therapies. The total consideration for the acquisition is expected to be around $12 million, paid in a staggered manner depending on the achievement of specific milestones. It also includes a provision for profit sharing based on future earnings generated by Utility's products. The transaction does not fall under the related party category, and none of the promoters or group companies have any financial interest in the deal. Completion of the acquisition is anticipated within approximately 30 days, and no additional regulatory approvals are required. This acquisition aligns with Alembic's strategy of expanding its global footprint and diversifying its product offerings in regulated markets like the US. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
